Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Altimmune (NASDAQ:ALT) in the last three months. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. In the assessment of 12-month price targets, analysts unveil insights for Altimmune, presenting an average target of $19.25, a high estimate of $25.00, and a low estimate of $12.00. Consistency is reflected as the current average remains at the same level as the previous average price target. …